Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade C 18.27 1.44% 0.26
IMMU closed down 5.21 percent on Wednesday, December 4, 2019, on 2.99 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical IMMU trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 1.44%
1,2,3 Pullback Bullish Bullish Swing Setup 1.44%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.44%
Doji - Bullish? Reversal 1.44%
MACD Bearish Signal Line Cross Bearish -3.84%
1,2,3 Pullback Bullish Bullish Swing Setup -3.84%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.84%
Pocket Pivot Bullish Swing Setup -3.84%
Outside Day Range Expansion -3.84%
Shooting Star Candlestick Bearish -2.72%

Older signals for IMMU ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Biotechnology Biopharmaceutical Cancer Immunology Treatment Of Cancer Monoclonal Antibodies Pharmacology Serious Diseases Pancreatic Cancer Humanized Antibody Non Hodgkin Lymphoma Lupus NHL Leukemias Cd20 Milatuzumab Treatment Of Lupus Treatment Of Non Hodgkin Lymphoma Treatment Of Pancreatic Cancer

Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicator Value
52 Week High 19.94
52 Week Low 11.55
Average Volume 2,063,399
200-Day Moving Average 15.5658
50-Day Moving Average 16.3242
20-Day Moving Average 18.097
10-Day Moving Average 18.684
Average True Range 0.7745
ADX 38.79
+DI 21.7586
-DI 19.6224
Chandelier Exit (Long, 3 ATRs ) 17.1965
Chandelier Exit (Short, 3 ATRs ) 19.3235
Upper Bollinger Band 19.4907
Lower Bollinger Band 16.7033
Percent B (%b) 0.47
BandWidth 15.402553
MACD Line 0.642
MACD Signal Line 0.7189
MACD Histogram -0.0769
Fundamentals Value
Market Cap 2 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -12.25
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.78
Resistance 3 (R3) 19.71 19.06 19.49
Resistance 2 (R2) 19.06 18.61 19.09 19.39
Resistance 1 (R1) 18.53 18.33 18.80 18.60 19.29
Pivot Point 17.88 17.88 18.01 17.91 17.88
Support 1 (S1) 17.35 17.43 17.62 17.42 16.73
Support 2 (S2) 16.70 17.15 16.73 16.63
Support 3 (S3) 16.17 16.70 16.54
Support 4 (S4) 16.24